ARCHIVES

Alan Rabson Outlasts Them All, Even His Bosses, As DCBD Chief

This article is from The Cancer Letter archive.

Vol. 08 No. 03 | January 15, 1982

Download PDF Visit The Full Archive

Related Articles

Conversation With The Cancer Letter: How ASCO’s Guideline Differs—And Why

July 20, 2012

Multiple Studies Show Benefit of CTL019, A Personalized Therapy, in CLL and ALL

December 27, 2013

Senate Committee Approves Additional $400 Million For NCI, $275 Million For FDA.

May 16, 2008

FDA Proposes “Clarification” Of Clinical Studies regulations, Including Sanctions, Inspections

August 18, 1978

Sarcoma Survivors At Risk Of Blood Clots, Study Finds

May 25, 2007

Survival For ALL Increased To 94 Percent In Recent Years

December 31, 2010